Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Key to changes
?
Text removedfrom 2019 Q1- Text added to 2019 Q2
Content analysis
?Positive | |
Negative | |
Uncertain | |
Constraining | |
Legalese | |
Litigous | |
Readability |
8th grade Avg
|
Content analysis
?Positive | |
Negative | |
Uncertain | |
Constraining | |
Legalese | |
Litigous | |
Readability |
8th grade Avg
|
New words:
AA, acid, andNew, Array, Aurobindo, boxed, bridge, CDK, cervical, cognitive, Colorado, conclusion, confirmed, consumption, contemplated, coupon, CreditWatch, decade, dilated, dual, Endothelial, enterprise, equate, excellence, formation, FORMSFOR, FTC, glioblastoma, hepatocellular, Hurricane, Inline, instance, Lamin, Les, lungcancer, lymphocytic, lymphoma, Maria, mCRC, microscopic, mitigate, notably, notch, NRDL, obligor, opioid, page, patientswith, pembrolizumab, potency, Presidential, pro, protein, rata, RCC, RESET, SAS, secondary, selectin, simultaneously, SmPC, strongest, symptomatic, TEC, thehead, transform, triple, underwritten, Vascular, VEGFR, vigorously, wholly, XBRL
Removed:
accompanied, adenocarcinoma, agent, aggressively, alfa, Amgen, antirheumatic, Apixaban, appealing, Asian, bleeding, Blueprint, bolivar, closely, communicate, communicated, consistent, conventional, de, death, DICOM, divested, EEA, epoetin, Epogen, exert, filgrastim, gastric, gastroesophageal, head, improvement, inadequate, Inspector, intolerant, limiting, long, medicinal, methotrexate, mixed, moderately, Neupogen, neuromuscular, neuroscience, observed, occurred, ovarian, overexpressing, Panel, partner, pharmacy, priced, Procrit, publish, RAR, recover, reducing, released, revalue, talazoparib, tanezumab, Trump, vehicle, vote, wrongful
Valuein 2019 Q1 filing- Value in 2019 Q2 filing
Original filings
Filing view